Study record
Comprehensive lifestyle change increases telomerase activity — pilot (Ornish et al., 2008)
Human pilot — telomerase-activity biomarker
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase expression is low in many differentiated normal tissues, while some normal proliferating cells can express it. Cancer can also use telomere maintenance; the included human records do not resolve long-term cancer risk from pharmacological activation. Tellingly, the FDA-approved telomerase inhibitor — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
○ Evidence tier 4 — Human pilot / observational — biomarker
Record verify: source publication identified; see evidence and limitations
| Design | Descriptive pilot study (telomerase-activity biomarker) |
| DOI | 10.1016/S1470-2045(08)70234-1 |
| Citation status | Original publication identity matched by title, author and DOI; relevant full-text sections, results and limitations examined 2026-10-14. |
Five-qualifier claim
| Species / population | Men with biopsy-proven low-risk prostate cancer on active surveillance (~30) — a small pilot cohort. |
| Exposure, route, schedule | 3 months of comprehensive lifestyle change (plant-based diet, exercise, stress management, group support). |
| Comparator / duration | Descriptive pilot; peripheral-blood-mononuclear-cell telomerase activity measured before and after 3 months. |
| Endpoint / numeric result | Increased PBMC telomerase activity after 3 months, associated with decreases in LDL cholesterol and psychological distress. |
| What it did NOT establish | A small descriptive pilot with a contested biomarker (telomerase activity), not a randomized, clinical-outcome, or lifespan result. |
Interventions
Primary reference
https://doi.org/10.1016/S1470-2045(08)70234-1
Each identifier above was confirmed against the primary record; the citation status names the source and the date. An identifier that could not be confirmed is left empty and named as such in the record, never filled in from a secondary source.